You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria
Login
Username:

Password:


Related Headlines

Sanofi and Teva report durable phase 2b maintenance efficacy for duvakitug in ulcerative colitis and Crohn's disease

Nucleome Therapeutics names new chief scientific officer

Eli Lilly and Company reports positive Phase 3 LIBRETTO-432 results for Retevmo in early-stage RET fusion-positive NSCLC

Celltrion data show subcutaneous infliximab restores disease control after treatment interruption

Cambridge Cognition expands into India through Ivory commercialisation agreement

Genentech reports positive Phase III MAJESTYdata for Gazyva in primary membranous nephropathy

Ella immunoassay platform gains CE‑IVD approval in the EU

HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer

MetaVia secures global patent protection for DA-1726

MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy

AstraZeneca reports positive Phase III results for BREZTRI in uncontrolled asthma

Centivax Inc doses first healthy volunteers in Centi-Flu 01 Phase 1A clinical trial

Innovent reports first participant dosed in Phase 3 trial of IBI354 for first-line treatment of HER2-positive breast cancer

Amgen wins European approval for Uplizna in generalised myasthenia gravis

Celyad Oncology sells C-Cathez catheter to CellProthera

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026